In a nutshell This study looked at the effect of surveillance scans after autologous stem cell transplantation (auto-SCT) in patients with relapsed or refractory diffuse large B-cell lymphoma. The study concluded that scanning everyone after auto-SCT has little benefit. Some background Diffuse large B-cell lymphoma (DLBCL) is the most common...
Read More
In a nutshell This study looked at the effect of autologous stem cell transplantation (auto-SCT) on patients with follicular lymphoma who have disease progression within 2 years of initial chemotherapy. The study found that patients who receive early auto-SCT have better survival rates than patients who do not receive auto-SCT. Some background...
Read More
In a nutshell This study determined the safety and effectiveness of combined brentuximab vedotin (Adcetris) and bendamustine (Treanda) for relapsed or refractory (did not respond to treatment) Hodgkin’s lymphoma (HL). The study concluded that this combination is safe and effective, even for patients who already received intense anticancer...
Read More
In a nutshell This study investigated the effects of abexinostat in patients with relapsed or refractory (did not respond to treatment) NHL (non-Hodgkin’s lymphoma). The study concluded that abexinostat is safe and effective in patients with NHL (particularly follicular lymphoma and diffuse large B-cell lymphoma). Some background Histone...
Read MoreIn a nutshell This study analyzed the outcomes of older patients with stage 3 or 4 DLBCL (diffuse large B-cell lymphoma) who received biosimilar filgrastim (Neupogen) during their chemotherapy. The study concluded that filgrastim was safe and effective in these patients. Some background Diffuse large B-cell lymphoma (DLBCL) is the most common type...
Read MoreIn a nutshell This study examined the impact of multi-drug resistant organisms in patients who had undergone stem cell treatment. The study concluded that patients colonized with multi-drug resistant organisms should be watched closely for infections after transplantation. Some background Stem cell transplantation is a treatment used in...
Read MoreIn a nutshell This study examined the impact of multi-drug resistant organisms in patients who had undergone stem cell treatment. The study concluded that patients colonized with multi-drug resistant organisms should be watched closely for infections after transplantation. Some background Stem cell transplantation is a treatment used in...
Read More
In a nutshell This study examined infection risk in leukemia and lymphoma patients treated with CAR-T cell therapy, a new type of immunotherapy. Researchers reported that infection rates were comparable to other salvage therapies. Some background Chimeric antigen receptor (CAR) T-cell therapy helps the immune system to fight cancer cells. In...
Read MoreIn a nutshell This study examined the effectiveness of lenalidomide (Revlimid) in patients with mantle cell lymphoma (MCL) already treated with ibrutinib (Imbruvica). The authors concluded that lenalidomide was effective following ibrutinib. Some background There is no standard-of-care treatment for patients with relapsed or refractory (did not...
Read More
In a nutshell This study looked at the effectiveness of bortezomib plus cyclophosphamide and rituximab at treating patients with relapsed mantle cell lymphoma. The study concluded that this combination of medication is safe and effective at treating patients with relapsed or difficult to treat mantle cell lymphoma. Some background Mantle...
Read MoreIn a nutshell This study looked at the safety and effectiveness of lenalidomide (Revlimid) to treat patients with relapsed diffuse large B-cell lymphoma. The authors concluded that lenalidomide is safe and effective for treating patients with relapsed diffuse large B-cell lymphoma, especially in patients with non-germinal center B-cell (GCB) like...
Read More
In a nutshell This study looked at the effect of rituximab maintenance therapy for mantle cell lymphoma patients who have already received an autologous stem cell transplantation. The study concluded that rituximab maintenance therapy greatly improves outcomes for patients with mantle cell lymphoma. Some background Mantle cell lymphoma (MCL)...
Read More
